

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandria, Vignua 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/891.865	06/25/2001	Giuseppina Bestetti	2901/0J410	2194	
75	08/26/2003				
DARBY & DARBY P.C.			EXAMINER		
	05 Third Avenue STEADMAN, DAVID		N, DAVID J		
			ART UNIT	PAPER NUMBER	
			1652	1.6	
			DATE MAILED: 08/26/2003 ( (		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.		Applicant(s)		
		09/891,865		BESTETTI ET AL.		
Office Action Summary		Examiner		Art Unit		
		David J Steadma	an	1652		
Period fo	The MAILING DATE of this communication or Reply	appears on the cove	r sheet with the co	rrespondence address		
THE - Exte after - If the - If NO - Failu - Any	ORTENED STATUTORY PERIOD FOR REMAILING DATE OF THIS COMMUNICATION INSIGNS of time may be available under the provisions of 37 CF SIX (6) MONTHS from the mailing date of this communication period for reply specified above is less than thirty (30) days, and period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by streply received by the Office later than three months after the mean patent term adjustment. See 37 CFR 1.704(b).	DN. R 1.136(a). In no event, how to a reply within the statutory mineriod will apply and will expire tatute, cause the application to	ever, may a reply be time nimum of thirty (30) days v SIX (6) MONTHS from th o become ABANDONED	ly filed will be considered timely the mailing date of this communication. (35 U.S.C. § 133).		
1)[	Responsive to communication(s) filed on	·				
2a) <u></u> □	This action is <b>FINAL</b> . 2b)⊠	This action is non-f	inal.			
3) Disposit	Since this application is in condition for all closed in accordance with the practice union of Claims	owance except for fo der <i>Ex parte Quayle</i> ,	ormal matters, pro 1935 C.D. 11, 45	secution as to the merits is 3 O.G. 213.		
4)[-	Claim(s) 31 and 33-60 is/are pending in the	e application.				
	4a) Of the above claim(s) is/are with	drawn from consider	ation.			
5)	Claim(s) is/are allowed.					
6)[	Claim(s) is/are rejected.					
7)	Claim(s) is/are objected to.					
8)[-	Claim(s) 31 and 33-60 are subject to restrict	ction and/or election	requirement.			
Applicati	on Papers		·			
9) 🗌 🤈	The specification is objected to by the Exam	niner.				
10)	The drawing(s) filed on is/are: a) $\Box$ a	ccepted or b) 🗌 object	ed to by the Exam	iner.		
	Applicant may not request that any objection t	o the drawing(s) be he	d in abeyance. See	e 37 CFR 1.85(a).		
11)	The proposed drawing correction filed on	is: a)∏ approve	ed b)⊡ disapprov	ed by the Examiner.		
	If approved, corrected drawings are required in	n reply to this Office ac	tion.			
12)	The oath or declaration is objected to by the	Examiner.				
Priority L	ınder 35 U.S.C. §§ 119 and 120					
13)💢	Acknowledgment is made of a claim for for	eign priority under 3	5 U.S.C. § 119(a)-	(d) or (f).		
a)[	☐ All b)☐ Some * c)ズ None of:					
	1.X Certified copies of the priority docum	ents have been rece	ived.			
	2. Certified copies of the priority documents have been received in Application No					
• 8	3. Copies of the certified copies of the papplication from the International see the attached detailed Office action for a	Bureau (PCT Rule	17.2(a)).	•		
14) 🗌 A	cknowledgment is made of a claim for dom	estic priority under 3	5 U.S.C. § 119(e)	(to a provisional application).		
	)  The translation of the foreign language Acknowledgment is made of a claim for dom					
Attachmen	t(s)					
2) Notic 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(	. —		PTO-413) Paper No(s) tent Application (PTO-152)		
S. Patent and Tr TOL-326 (R		e Action Summary		Part of Paper No. 11		

Application/Control Number: 09/891,865

Art Unit: 1652

## **DETAILED ACTION**

## Status of the Application

- [1] Claims 31 and 33-60 are pending in the application.
- [2] Applicant's cancellation of claims 1-30 and addition of claims 31-60 in Paper No. 10, filed June 25, 2001 is acknowledged.
- [3] Receipt of a computer readable form (CRF) of the sequence listing, a paper copy thereof, and a statement that the CRF and paper copy are identical filed as Paper No. 5, is acknowledged.
- [4] Applicant's amendment to the specification in Paper No. 6, filed October 9, 2001 is acknowledged.
- [5] Applicant's cancellation of claim 32 in Paper No. 8, filed February 02, 2002, is acknowledged.
- [6] Receipt of an information disclosure statement filed as Paper No. 1 is acknowledged.
- [7] It is noted that the foreign priority document has not been filed in the instant application.

  Applicant states the foreign priority document "will follow". See 35 USC 119(b).

## Election/Restrictions

- [8] Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 31 and 33-48, 58, and 59, drawn to a recombinant plasmid expression vector comprising a first gene and/or a second gene, prokaryotic host cells, and a method for producing polypeptides using said host cells, classified in class 435, subclass 193.
  - II. Claims 49-57, drawn to a method of catalyzing transglycosylation using host cells or the crude or purified extract thereof, classified in class 435, subclass 128.
  - III. Claim 60, drawn to a fusion protein, classified in class 435, subclass 193.
- [9] The inventions are distinct, each from the other because:
- [10] The nucleic acid Group I and the polypeptide of Group III each comprises a chemically unrelated structure capable of separate manufacture, use and effect. The nucleic acid of Group I has other utility

Page 3

Application/Control Number: 09/891,865

Art Unit: 1652

besides encoding polypeptides such as being used as a hybridization probe or PCR template and the polypeptide of Group III can be made by another method such as chemical synthesis.

- [11] The host cell comprising the nucleic acid of Group I and the method of Group II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the host cell of Group I can be used for expression of the protein of Group III.
- [12] The polypeptide of Group III and the method of Group II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polypeptide of Group III can be used as an antigen in the production of an antibody.
- [13] MPEP § 803 sets forth two criteria for a proper restriction between patentably distinct inventions:

  (A) The inventions must be independent or distinct as claimed and (B) There must be a serious burden on the examiner. As shown above, each of the inventions of Groups I-III are independent or distinct, thus satisfying the first criterion for a proper restriction. MPEP § 803 additionally states that a serious burden on the examiner may be prima facie shown if the examiner shows by appropriate explanation either separate classification, separate status in the art, or a different field of search. Each of the inventions has separate classification and/or requires a separate patent and non-patent literature search requiring a different text and/or sequence search for each Group and thus, co-examination of the inventions of Groups I-III would place a serious burden on the examiner.
- [14] Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 09/891,865 Page 4

Art Unit: 1652

[15] Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Steadman, whose telephone number is (703) 308-3934. The Examiner can normally be reached Monday-Friday from 7:00 am to 5:00 pm. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (703) 308-3804. The FAX number for submission of official papers to Group 1600' is (703) 308-4242. Draft or informal FAX communications should be directed to (703) 746-5078. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Art Unit receptionist whose telephone number is (703) 308-0196.

David J. Steadman Patent Examiner Art Unit 1652

A 108/18/03